Evercore ISI reiterates IBM stock rating on solid quarter results By Investing.com

IBM reported Q1 revenue of $15.9 billion and EPS of $1.91, both ahead of expectations of $15.6 billion and $1.81. Management kept 2026 revenue growth guidance above 5% year-over-year, raised Software segment growth guidance to above 10% at constant currency, and reaffirmed free cash flow guidance of about $1 billion higher year-over-year. The company also signaled openness to further software M&A after the Confluent acquisition, while Evercore ISI reiterated Outperform and BofA maintained Buy.

Analysis

IBM’s real read-through is not the print itself, but the re-acceleration in software mix and management’s willingness to keep buying growth. That combination tends to compress the gap between “defensive legacy compounder” and “AI infrastructure beneficiary,” which supports multiple expansion more than the headline revenue beat does. The market is likely underestimating how much of IBM’s valuation can re-rate if software stays above a 10% constant-currency growth path for several quarters while FCF remains structurally >$10B annualized.

The second-order winner may be CFLT, but not in the obvious “IBM is a competitor” sense. If IBM continues to use M&A to fill platform gaps, that signals a consolidator phase in enterprise data and middleware, which can lift strategic value for asset-light software targets even when their stand-alone growth is merely average. For Intel, the Tesla Terafab signal is more about validation than volume: any credible 14A design win helps de-risk the node and could improve customer conversations, but the market should be careful not to extrapolate a single marquee announcement into broad foundry share gains.

TSLA’s relevance is asymmetric: if Terafab is real and material, it strengthens Tesla’s vertical integration narrative, but it also increases execution risk because fab ambition is capital-intensive and operationally unforgiving. For INTC, the gap between announcement and revenue remains the critical risk window; this is a multi-year story, not a next-quarter catalyst. The consensus may be underpricing IBM’s free-cash-flow durability and overpricing the immediacy of Intel’s foundry monetization.

Key Decisions for Investors

• Long IBM vs short a basket of slower-growing large-cap software names over the next 3-6 months; use a pair structure to isolate re-rating potential from multiple compression elsewhere. Risk/reward favors IBM if software growth holds and M&A remains disciplined.
• Buy IBM call spreads 3-6 months out to express a valuation re-rate with capped premium outlay; target a move toward the high end of Street multiples if FCF guidance is reaffirmed again. Cut if software growth slips below the low-teens constant-currency range.
• Maintain a tactical long INTC only on pullbacks, with a 6-12 month horizon; this is a sentiment trade on foundry credibility, not a fundamental all-clear. Use tight risk controls because conversion from design win to revenue is long-dated and easily delayed.
• Avoid chasing TSLA solely on the Terafab headline; if anything, treat it as a long-dated optionality enhancer rather than an earnings driver. Preferred expression is a small call-spread position, not common stock overweight.
• Watch CFLT for strategic upside if IBM’s M&A appetite broadens; a basket approach to enterprise data software may capture acquisition premium before it is fully priced in.